| Full text | |
| Author(s): |
Total Authors: 3
|
| Affiliation: | [1] Univ Sao Paulo, Fac Ciencias Farmaceut, Dept Farm, Av Prof Lineu Prestes, 580 Bloco 15, Cidade Univ, BR-05508000 Sao Paulo, SP - Brazil
Total Affiliations: 1
|
| Document type: | Journal article |
| Source: | JOURNAL OF AOAC INTERNATIONAL; v. 104, n. 3, p. 585-591, MAY-JUN 2021. |
| Web of Science Citations: | 1 |
| Abstract | |
Background: Conformity assessment in pharmaceutical drug products usually are based on analytical results. An analytical result always is associated with an uncertainty which must be considered in a compliance assessment. Objective: The objective of the present project aims to estimate the measurement uncertainty associated with the results of average weight, assay, uniformity of content, and dissolution testing in ranitidine tablets manufactured by two different companies (X and Y). Methods: The uncertainty was evaluated using the Monte Carlo method. The particular and total risks of false acceptance decisions (consumers' risks) were also estimated by the Monte Carlo method. Results: The results for ranitidine tablets manufactured by company X were (359.22.7) mg of average weight, (108.61.6)% of assay, (11.4 +/- 2.8) of acceptance value for uniformity of content, and (89.4 +/- 1.3)% for dissolution testing. The results for company Y were (312.5 +/- 0.9) mg, (107.0 +/- 1.4)%, (7.2 +/- 1.7), and (93.6 +/- 1.3)%, respectively. A 95% confidence level was adopted. According to results obtained from the Monte Carlo simulations, the results of average weight, assay of ranitidine, and uniformity of content are significantly correlated due to shared analytical steps. The correlation between values significantly affected the risk of false decisions. Conclusions: Consumers' risks were estimated for both ranitidine tablets and their results ensure compliance for ranitidine tablets manufactured by companies X and Y. Highlights: The use of measurement uncertainty is an important issue regarding the conformity/non-conformity assessment of pharmaceutical products. (AU) | |
| FAPESP's process: | 19/16206-3 - Risks of false decisions due to the measurement uncertainties in the evaluation of pharmaceutical equivalence |
| Grantee: | Felipe Rebello Lourenço |
| Support Opportunities: | Regular Research Grants |